TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06172127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: 10 mL type 1 amber borosilicate glass vial sealed with a fluoro-resin laminated butyl rubber stopper, and a polypropylene/aluminium yellow flip-off crimp cap. One vial of powder for concentrate for solution for IV infusion contains 100 mg of T-DXd. The drug product also contains L-histidine, L-histidine hydrochloride monohydrate, Sucrose, and Polysorbate 80.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
Description: 20 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Description: 15 mL type I borosilicate glass vial tapered with fluororesin-laminated rubber stopper sealed with aluminum and covered by a cool green plastic flip-off cap, containing 10 mL solution of 600 mg of pertuzumab and 600 mg of trastuzumab.
Study: NCT05358145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tinkering Activities
Description: Tinkering activities are activities that comprise elements of science, art, and technology. Through a series of themes objectives, participants can involve interestingly, creatively, and flexibly in the activity when they fulfill the goal with the materials retrievable at the site. Participants will be trained as they involve in the elements hidden within the core of the training, such as problem exploration, active thinking and inference, trial and error, and problem-solving.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Tinkering Activities
Description: Controlled Tinkering Activities utilize the themes of Tinkering activities but eliminate the core of Tinkering training, hence implementing a new set of activities that emphasize participants strictly follow procedures to complete the similar objective of Tinkering activities. Each participant will end up with a similar piece of work as Tinkering Activities participants would without problem exploration, active thinking and inference, trial and error, and problem-solving.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Board Games Activities
Description: Board games are often constructed with concepts of different cognitive components, such as attention, working memory, planning, calculation; therefore serve as a commonly seen cognitive training, while more and more literature continues to support tabletop games being the medium of cognitive promotion.
Study: NCT06383390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06345430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exopulse Molli-Suit (Wearable Technological Device)
Description: After initial evaluations, patients will receive Exopulse Mollii Suit in a single session for 1 hour. The stimulation level of the electrodes will be automatically generated by the system in accordance with the pain level specified by the patients for their body parts before the application.
Study: NCT05151653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765250
Description: BI 765250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04835103

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CM
Description: Case management, a case manager will actively contact and follow the patient's physical and psychological conditions, and provide disease-specific psychoeducation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: P/T
Description: Psychotherapy, based on both cognitive-behavioral therapy and biofeedback therapy, structuralized, 6-10 sessions, performed by a psychiatrist or psychologist
Study: NCT05932836

Intervention type: OTHER
Intervention: No interventions.
Description: No interventions to be administered.

Intervention type: OTHER
Intervention: No interventions.
Description: No interventions to be administered.
Study: NCT06544135

Intervention type: DEVICE
Intervention: FLIR One Pro LT
Description: Thermal imaging camera used to measure temperatures of the lower limb.
Study: NCT05741372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochlorid
Description: Metformin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochlorid
Description: Metformin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochlorid
Description: Metformin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide
Study: NCT05365581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2138
Description: Intravenously or Subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2138
Description: Intravenously or Subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2138
Description: Intravenously or Subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2138
Description: Intravenously or Subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2138
Description: Intravenously or Subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2138
Description: Intravenously or Subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2138
Description: Intravenously or Subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2138
Description: Intravenously or Subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2138
Description: Intravenously or Subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenously
Study: NCT06321302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764524
Description: BI 764524

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham comparator to BI 764524
Description: Sham comparator to BI 764524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept (Eylea®) - US only
Description: Aflibercept (Eylea®) - US only
Study: NCT06277934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT001-075
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06233903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-mFBG
Description: 18F-mFBG positron emission tomography with CT (PET/CT) or positron emission tomography with MRI (PET/MRI)
Study: NCT06274515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Tissue and Blood Draw
Description: Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Tissue and Blood Draw
Description: Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.
Study: NCT05555069

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Menthol-flavored electronic cigarette
Description: Participants will receive 12 weeks of menthol -flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco-flavored electronic cigarette
Description: Participants will receive 12 weeks of tobacco-flavored electronic cigarettes to aid in switching from combustible cigarettes. Participants will be instructed on proper use of the electronic cigarettes, educated about electronic cigarettes and participate in motivation enhancement and substituting electronic cigarettes for cigarettes.
Study: NCT05930496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive exercise intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Receive tele-coaching intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Receive health-related information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05509777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV or SC
Study: NCT06061770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity program
Description: Rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted physical activity self-program
Description: Rehabilitation
Study: NCT05278260

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen tablets
Description: Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that releases molecular hydrogen, for the duration of the radiation therapy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will drink up to 1000 ml (34 fl. oz.) of water daily supplemented with a tablet that does not release any molecular hydrogen, for the duration of the radiation therapy
Study: NCT06192095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin barrier film
Description: Preventive use of skin barrier film after insertion of a vascular indwelling catheter before covering with transparent dressing +/- gauze
Study: NCT06640413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-OncoFAP-23
Description: 3.7, 7.4, or 11.1 GBq to define the RD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-OncoFAP-23
Description: 3.7, 7.4, or 11.1 GBq to define the RD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-OncoFAP-23
Description: 3.7, 7.4, or 11.1 GBq to define the RD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-OncoFAP-23
Description: 3.7, 7.4, or 11.1 GBq to define the RD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-OncoFAP-23
Description: 3.7, 7.4, or 11.1 GBq to define the RD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-OncoFAP-23
Description: 3.7, 7.4, or 11.1 GBq to define the RD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-OncoFAP-23
Description: 3.7, 7.4, or 11.1 GBq to define the RD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2
Description: 22.5 Mio IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2
Description: 22.5 Mio IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2
Description: 22.5 Mio IU
Study: NCT04949841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib
Description: Delgocitinib cream 20 mg/g
Study: NCT05699772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI)
Description: The GLB-TBI was modified from the Diabetes Prevention Program Group Lifestyle Balance (DPP-GLB) by a group of stakeholders using a community based participatory research approach. The GLB-TBI is modified for people with Traumatic Brain Injury and addresses their unique weight loss and healthy lifestyle needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Group (BHG)
Description: The BHG was developed by researchers and clinicians at Baylor Scott \& White Institute for Rehabilitation.
Study: NCT05411887

Intervention type: DRUG
Intervention: Rosuvastatin, Olmesartan Medoxomil
Description: Olostar Tablet
Study: NCT04035629

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MagniXene, hyperpolarized 129Xe MRI
Description: All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung. Hyperpolarized 129Xe gas is prepared in a process termed spin-exchange optical pumping.~Xenon is highly lipophilic and therefore soluble in blood and tissue, making it an excellent tool for imaging the gas in both the air spaces (gas-phase imaging) and dissolved in the lung parenchyma (dissolved-phase imaging). This solubility in combination with xenon's chemical shift properties, results in the possibility of quantifying pulmonary gas exchange and gas transport within the parenchyma.~Additionally, previous images and lung function tests will be reviewed to compare findings and evaluate if there is a correlation between the obtained results.
Study: NCT05929599

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo Navax
Description: In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.
Study: NCT06192485

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: proactive balance training
Description: 20 participants will receive a proactive balance training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reactive balance training
Description: 20 participants will receive a Reactive balance training program
Study: NCT06579092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet once daily during 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet once daily during 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet once daily during 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet once daily during 36 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet once daily during 36 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching AZD5004 film-coated tablet once daily during 36 weeks
Study: NCT05050149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTX-022
Description: Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
Study: NCT06510842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External drainage of intraventricular hemorrhage
Description: An EVD is required to be eligible for the DRAIN IVH study. Weaning from the EVD is at the discretion of the local investigators. Imaging is at discretion of local investigators. Use, timing and frequency of fibrinolysis via EVD is at local discretion, too.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External drainage of intraventricular hemorrhage
Description: An EVD is required to be eligible for the DRAIN IVH study. Weaning from the EVD is at the discretion of the local investigators. Imaging is at discretion of local investigators. Use, timing and frequency of fibrinolysis via EVD is at local discretion, too.
Study: NCT06579105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (placebo matching AZD5004 film-coated tablet)
Description: Placebo film-coated tablet (matching AZD5004)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet, once daily during 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet, once daily during 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet, once daily during 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet, once daily during 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet, once daily during 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5004
Description: AZD5004 film-coated tablet, once daily during 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: 3-14 mg tablets of Semaglutide
Study: NCT06104319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered
Study: NCT05898412

Intervention type: DRUG
Intervention: Andexanet alfa
Description: Patients treated with andexanet alfa
Study: NCT04169243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Nordic Diet
Description: The New Nordic Diet conforms with the Nordic Nutrition Recommendations and incorporates environmental sustainability and planetary health. It includes rapeseed oil, whole grain bread, wild fish, seafood and game, potatoes, root vegetables, cabbages, Nordic fruits and berries. A two-week menu including all daily meals has been created to ensure dietary goals of the New Nordic Diet intervention: fish and shellfish intake ≥ 3 times/w (fatty fish at least once per week), ≥ 500 g fruit, berries, vegetables and legumes daily (legumes as main protein source at least twice per week), whole-grain cereal products, rapeseed oil for cooking/dressing and three table spoons of nuts and seeds per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control women receive diet advice according to usual care, which may be a short meeting with the regular midwife or a short meeting with a dietician. From the study, they will receive a gift certificate that can be used in grocery stores.
Study: NCT06393062

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.
Description: Gram staining of the first urine after intraoperative renal puncture to predict the systemic inflammatory response after percutaneous nephrolithotomy.
Study: NCT05761301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-KHK
Description: ALN-KHK will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-KHK
Description: ALN-KHK will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by subcutaneous (SC) injection.